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Heparan sulfate, the polysaccharide side chain of 
heparan sulfate proteoglycan, is important for the perm- 
selective properties o f the glomerular basement mem­
brane. In this report, we show a role for hydroxyl radi­
cals in  heparan sulfate degradation and an enhanced  
glomerular basem ent membrane permeability. First, in 
enzyme-linked immunosorbent assay, exposure of 
coated heparan sulfate (proteoglycan) to reactive oxy­
gen species resulted in  a ±50% decrease of binding of a 
monoclonal antibody against heparan sulfate, whereas 
binding of an antibody against the core protein re­
mained unaltered. Second, on polyacrylamide gel elec­
trophoresis, the molecular weight of heparan sulfate 
exposed to radicals was reduced which indicates depo­
lymerization. Both in enzyme-linked immunosorbent as­
say and gel electrophoresis, hydroxyl radicals are in­
strumental for heparan sulfate degradation as shown by 
the addition of various radical scavengers. Third, in an 
experimental model for human nephrotic syndrome (Ad- 
riamycin nephropathy in rats), glomerular basement 
membrane staining of two recently described anti-hepa­
ran sulfate antibodies (JM403 and KJ865) was reduced 
by 24 and 43%. Treatment of Adriamycin-exposed rats 
with the hydroxyl radical scavenger dimethylthiourea 
both reduced albuminuria by 37% (p < 0.01) and partly 
prevented loss of heparan sulfate staining by 53% 
(JM403) and 39% (KJ865) (p < 0.03). In contrast to the 
heparan sulfate side chains, the core protein expression  
and the extent of glycanation did not change in Adriamy- 
cin nephropathy. We conclude that glomerular basement 
membrane heparan sulfate is susceptible to depolymer­
ization by hydroxyl radicals leading to loss of glomerular 
basement membrane integrity and albuminuria.
Heparan sulfate (HS)1 is the anionic polysaccharide side 
chain of heparan sulfate proteoglycan (HSPG) present in base­
ment membranes, extracellular matrix, and on the cell surface 
of many (if not all) cell types (1-3). Several investigators have
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shown that HS plays an important role in the permselective 
properties of the glomerular basement membrane (GBM) (4, 5). 
Enzymatic digestion of HS by heparitinase resulted in an in­
creased passage of native ferritin and albumin through the 
GBM (6, 7). Furthermore, intravenous injection of a mono­
clonal antibody (mAb) directed against HS induces acute, se­
lective proteinuria in rats (8). A reduction in GBM HS-associ- 
ated anionic sites was found with cationic probes in several 
human and experimental proteinuric glomerulopathies (9, 10). 
With recently developed antibodies directed against GBM 
HSPG core protein and the HS side chain (11, 12), we demon­
strated a decrease in HS staining in the GBM in different 
human proteinuric glomerulopathies, whereas the staining of 
the HSPG core protein remained unaltered (13). The mecha­
nism responsible for this observation remains to be elucidated. 
In lupus nephritis, masking of HS by autoantibodies complexed 
to nucleosomes is proposed as a mechanism for the decrease in 
HS staining and albuminuria (14). In hum an and experimental 
diabetic nephropathy, it was suggested that the decrease in HS 
staining was due to loss of HS from the GBM (15, 16). These 
mechanisms, however, are not likely to occur in other glomer­
ular diseases (13).
Previous reports have shown th a t reactive oxygen species 
(ROS) are able to degrade proteoglycan core proteins (17, 18) 
and glycosaminoglycans including HS and heparin (19-23) or 
can inhibit de novo synthesis of proteoglycans (17, 24). Further­
more, ROS were demonstrated to be involved in experimental 
glomerulopathies such as Adriamycin (ADR) nephropathy (25), 
puromycin aminonucleoside nephrosis (26), passive Heymann 
nephritis (27), and anti-GBM nephritis (28). ROS have been 
shown to cause proteinuria (29, 30) and loss of HS in the 
isolated perfused kidney model (29).
These data suggest tha t loss of GBM HS staining in various 
types of human glomerulopathies (13) might be secondary to 
the local production of ROS. To this end, we performed in vitro 
and in vivo experiments to evaluate the effects of ROS on GBM 
HSPG and HS and on GBM permeability. As major tools we 
used a set of four antibodies directed against various epitopes 
of HS(PG) as follows: JM403 (12) and KJ865 (31) which are 
directed against different domains in the HS side chain of 
HSPG, 3G10 which is directed against an epitope of HS that is 
generated by digestion of HSPG with heparitinase (32), and 
BL31 which is directed against the HSPG core protein (33). In 
enzyme-linked immunosorbent assay (ELISA), we studied the 
effects of ROS on immobilized HS from bovine kidney or HSPG 
isolated from ra t GBM. On polyacrylamide gel electrophoresis 
(PAGE), we evaluated the effect of ROS on the  molecular 
weight of HS. Identification of the radical(s) primarily involved 
in HS alteration was performed by the use of specific oxygen 
radical scavengers. To investigate the physiological signifi­
cance of ROS on GBM HSPG expression and GBM permeabil­
ity, we evaluated HS alterations in the nephrotic syndrome in 
rats after intravenous injection of ADR (doxorubicin, a member
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of the anthracyclin family), since in this model the generation 
of ROS has been shown (25, 34). The impact of ROS on G-BM 
HSPG and HS expression and albuminuria in this model was 
investigated by intervention studies with radical scavengers. 
Our results indicate th a t hydroxyl radicals are important for 
both GBM HS degradation and increased GBM permeability in 
ADR nephropathy in rats.
MATERIALS AND METHODS 
In  Vitro Generation o f  R O S
To study the effect of ROS on HS in vitro, ROS were generated via the 
hypoxanthine-xanthine oxidase system and the iron-catalyzed Haber- 
Weiss reaction according to the method described by Moseley et a l  (19). 
In this system, Oa, H20 2, and ’OH are formed as is indicated by the 
following Equations 1-4.
3G10 KJ865
JM403
Xanthine oxidase 
hypoxanthine xanthine -t- uric acid + 0 2
20g + 2H+ —> H2O2 + O2
Fe3+ + O, Fe24* + 0 2 
*OH + OH' + Fe3+Fe2+ + H20 2
(Eq. 1) 
(Eq. 2) 
(Eq, 3) 
(Eq. 4)
Hypoxanthine (HX, Sigma) and xanthine oxidase (XO, Sigma, grade III 
from buttermilk) were dissolved in a buffer containing 50 mM K^HPO^ 
pH 7,8, 1 mM EDTA, and (unless stated otherwise) 50 ¡m Fea+-EDTA 
chelate and incubated in the wells of an HS-coated micro titer plate for 
2 h at 37 °C in the presence or absence of various concentrations of 
superoxide dismutase (SOD, EC 1.15.1.1 from bovine erythrocytes, 
Sigma; concentration range from 0.15-2500 units/ml), dimethylthio- 
urea (DMTU, Sigma; from 0.003 to 50 mg/mi), or deferoxamine (DFO, 
Ciba-Geigy AG, Basel, Switzerland; from 0.003 to 50 mg/ml). HS was 
also exposed to HX and XO in an iron-free buffer. The ELISA was 
performed as described below. For PAGE, HX and XO were incubated 
with 20 /xg of HS for 2 h at 37 °C in the presence or absence of either 625 
units/ml SOD, 1 mg/ml DMTU, or 12.5 mg/ml DFO, HS was also 
exposed to HX and XO in an iron-free buffer. Then, the sample was 
boiled for 5 min to inactivate XO, centrifuged for 10 min at 13,000 rpm, 
and loaded on. a polyacrylamide gradient gel (35). As molecular weight 
markers, we used heparin-derived octasaccharides, hexasaccharides, 
and tetrasaccharides (obtained after deamination by nitrous acid at pH 
1.5 followed by sieve chromatography; kindly provided by Dr, G. van 
Dedem, Diosynth, Oss, The Netherlands). The gel was run at 250 V for 
18 h and subsequently stained with Alcian blue and ammoniacal silver, 
according to the method described by Lyon and Gallagher (35).
Antibodies
For ELISA and immunofluorescence (IF) (see below), we used various 
antibodies directed against different epitopes of HS(PG) as follows: two 
mAbs that recognize different epitopes in the HS chain, mouse mAb 
JM403 which is directed against lo w-aulfated domains of HS containing 
an iV-unsubstituted glucosamine unit (8, 12), and mouse mAb KJ865 
which is directed against JV-acetylated domains of HS (31); goat poly­
clonal antibody BL31 which is directed against the core protein of 
HSPG (33) and mouse mAb 3G10 which recognizes HS stubs generated 
by digestion with heparitinase (32). By this treatment, a terminal 
4,5-unsaturated uronate residue is formed that is essential for recog­
nition by 3G10. The staining by 3G10 can serve as a general HS marker, 
independent of the extent of HS modification. Fig. 1 shows schemati­
cally the general structure of an HSPG molecule and the binding sites 
of the four antibodies used in this study.
E L ISA
HS (from bovine kidney; Seikagaku Kogyo, Tokyo, Japan) was coated 
to a polystyrene flat-bottom microtiter plate (NUNC Maxisorp; Life 
Technologies, Inc., Breda, The Netherlands) in a concentration of 50 
/xg/ml in phosphate-buffered saline (PBS), 100 ¿ilAvell, overnight at 
room temperature. Alternatively, HSPG, isolated from ra t GBM as 
described earlier (31), was coated 1 jug/ml in PBS, 100 ^1/well, overnight 
at room temperature. After washing 6 times with PBS, HX and XO were 
added in an end volume of 100 ^1/well for 2 h a t 37 °C. Thereafter, the 
plates were washed 6 times with PBS and incubated with 1% gelatine 
(Difco) in PBS, 150 fil/well, for 2 h  at room temperature to prevent 
nonspecific binding. After washing 6 times with PBS containing 0.05%
Fig. 1. Schem atic rep re sen ta tio n  of a n  HSPG m olecule. The
binding sites of four antibodies directed against different domains of 
HSPG are indicated. O, HSPG core protein; HS stub after hepariti­
nase digestion; —, iV-acetylated domain in HS; □  mixed N-acetylated 
and iV-sulfated domain in HS containing iV-unsubstituted glucosamin 
residue; ■ high sulfated (heparin-like) domain in HS.
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F ig . 2 . Effect of various doses of h y poxan th ine  and /or x an ­
th in e  oxidase on HS. Coated HS was incubated for 2 h at 37 °C with 
hypoxanthine (□), xanthine oxidase (A), or both (• )  in various dilutions 
starting with 7.36 mM HX and 50.4 miiliunits/mi XO. Then, ELISA was 
performed with anti-HS mAb JM403.
Tween 20 (PBS/Tween), the wells were incubated with anti-HS side 
chain mAb JM403 1:50,000 or anti-HSPG core protein antibody BL31 
1:2,000 in PBS/Tween, 100 /xl/well, for 1 h at room temperature. There­
after, the wells were washed 6 times with PBS/Tween and incubated 
with either 100 ¡A of peroxidase-labeled ra t anti-mouse Ig (light chain 
type kappa) (RM19; Central Laboratory for Blood Transfusion, Amster­
dam, The Netherlands) 1:1,500 in PBS/Tween or with peroxidase-la­
beled rabbit anti-goat Ig (Dakopatts, Glostrup, Denmark) 1:2,000 in 
PBS/Tween for 1 h at room temperature. Then, the wells were washed 
9 times with PBS/Tween and incubated with 100 ¡x\ of tetramethylben- 
zidine substrate solution that was prepared immediately before use 
(SFRI Laboratories, Berganton, France). After 20 min, the reaction was 
stopped with 2 M H2S04, and absorption was measured at a wavelength 
of 450 nm using a Bio-Rad Multiplate Reader.
Animals
For all experiments, we used male Wi star-Unilever rats that were 
bred a t our animal laboratory and weighed 150-200 g at the start of the 
experiments. The animals were fed standard food and tap water ad 
libitum.
Experimental Design
Time Response Study — In a previous study (36), we compared differ­
ent doses of ADR. We found that a dose of 5 mg/kg body weight (BW) 
Adriamycin® (Adriablastina; Farmitalia, Milan, Italy) was optimal to 
induce proteinuria. To study the time course of ADR nephropathy, 40 
animals were injected with 5 mg of ADR/kg BW and after either 1-5 
weeks 8 rats were sacrificed, and their kidneys were snap-frozen in 
liquid nitrogen and used for IF. Urine and serum samples were col-
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F ig . 3. Effect of ROS on HS an d  HSPG in  vitro. Coated HS (A, B, and C) or HSPG from ra t GBM (D, E t and F) were incubated with 
hypoxanthine and xanthine oxidase for 2 h at 37 °C in the presence of various concentrations of superoxide dismutase (A andD), dimethylthiourea 
CB and E), or deferoxamine (C and F). Then ELISA was performed with anti-HS mAh JM403 (A~F, • )  and anti-HSPG core protein antibody BL31 
(D-F, O).
lected every week to determine albumin and IgG concentrations. Clear­
ance of albumin was calculated as urine albumin excretion per 24 
h/serum albumin concentration, and selectivity index was calculated as 
clearance IgG/clearance albumin.
Treatment with ROS Scavengers — To study the involvement of ROS 
in ADR nephropathy, 22 rats received an injection of 5 mg of ADR/kg 
BW and were treated with ROS scavengers. One group (n = 8) received 
an initial intraperitoneal injection of 500 mg of DMTU/kg BW dissolved 
immediately before use in saline 6 h before the ADR injection, followed 
by intraperitoneal injections of 125 mg of DMTU/kg BW twice daily (at
8.00 and 20.00 h) for 7 days, starting 6 h after ADR injection. The other
2 groups (both n ~ 7) received either 52,600 units of SOD/kg BW 
dissolved immediately before use in saline or the same volume of saline 
intraperitoneally twice daily (at 8.00 h and 20.00 h) for 7 days starting
6 h before ADR injection. These doses are in accordance with other 
studies, where they were found to be effective (26, 37-39).
Urine was collected every week to determine albuminuria, and 4 
weeks after the ADR injection, the rats were killed and their kidneys 
were snap-frozen in liquid nitrogen and used for indirect IF.
Determination of Urine and Serum Albumin
and IgG Concentration
Urinary albumin excretion was measured in urine collected for 24 h 
in metabolic cages. Urine and serum concentrations of albumin were 
determined by rocket immunoelectrophoresis (40), with goat anti-rat 
albumin and ra t albumin as a standard (both from Nordic, Tilburg, The 
Netherlands). Urine and serum IgG concentrations were determined by 
ELISA (8).
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Assessment of HS and HSPG Staining in the GBM by Indirect IF
Indirect IF was performed as described previously (11, 13) on 2-ju.m 
cryostat sections of rat kidneys that were fixed during 10 min in acetone 
at 4 °C (except for the sections tha t were digested by heparitinase to 
allow staining with 3G10). All antibodies were diluted in PBS contain­
ing 1% BSA and 0.1% sodium azide (IF buffer) and were incubated for 
45 min at room temperature. Sections were incubated with mAb KJ865 
diluted 1:20, followed by FITC-labeled goat anti-mouse IgM Fc-specific 
(Nordic, Tilburg, The Netherlands), diluted 1:50 in IF buffer containing 
4% normal ra t serum. To evaluate the GBM HS staining with a mAb 
directed against an epitope of HS that is generated by digestion with 
heparitinase, non-fixed sections were incubated for 1 h at 37 °C with 
0.25 units/ml heparitinase (heparin-sulfate lyase, EC 4.2.2.8, Sigma) in 
50 mM HEPES and 10 mM CaCl2, pH 7.0. Next, the sections were 
incubated with mAb 3G10 diluted 1:200 in IF buffer, followed by incu­
bation with FITC-labeled goat anti-mouse IgG2b (Southern, Birming­
ham, AL) diluted 1:100 in IF buffer containing 5% normal ra t serum. 
Sections were double-stained with goat anti-human GBM HSPG core 
protein BL31 and mouse anti-rat GBM HS mAb JM403. Sequential 
incubations were performed as follows: 1) goat anti-HSPG core protein 
BL31, diluted 1:400; 2) FITC-labeled rabbit anti-goat IgG (De Beer 
Medicals, Diessen, The Netherlands), diluted 1:500 in IF buffer con­
taining 4% normal rat serum; 3) mouse anti-HS mAb JM403, diluted 
1:800; 4) TRITC-labeled goat anti-mouse IgM Fc-specific (Nordic, Til­
burg, The Netherlands), diluted 1:25 in IF buffer containing 4% normal 
rat serum. The double staining experiments included the following 
controls: 1) omitting BL31 or JM403 or both; 2) incubating BL31 or 
JM403 with the conjugate used for the detection of the other antibody 
in the double staining.
After incubation with antibodies the sections were washed with PBS 
and embedded in Vectashield mounting medium H-1000 (Vector Labo­
ratories Inc., Burlingame, CA) and examined with a Zeiss Axioskop 
microscope equipped with an epi-illuminator. The staining intensities 
of the antibodies in the GBM were scored in 25 glomeruli on a scale 
between 0 and 10. No GBM staining was given a score of 0, and 10% of 
the GBM positive was given 1, 20% positive was given 2, etc., and all 
GBM loops positive were given 10. Therefore, the maximal score for the 
staining in each section was 250 arbitrary units (AU), The scoring was 
performed by two independent observers on coded sections, and the 
mean of the two scores was used for further analysis, As described 
previously the inter-observer variation is low (41).
Statistical Analysis
For statistical analysis, the Mann-Whitney U test and the ANOVA 
for repeated measurements were used for inter-group comparisons. To 
test cor relationships, the Spearman rank correlation test was used. A p  
value of less than  0.05 was considered significant.
RESULTS
Effect of R O S  on HS(PG) in Vitro—To find optimal concen­
trations of HX and XO, concentration ranges from 0,002 to 7.36 
m M  HX and from 0.01 to 50.4 milliunits/ml XO were tested on 
coated HS in ELISA (Fig. 2). The optimal concentrations of HX 
and XO were chosen such that both components alone had no 
effect on the ELISA signal, and the combination resulted in a 
maximal decrease of JM403 signal on coated HS. The optimal 
concentrations were 1.84 m M  HX and 12.6 milliunits/ml XO, 
resulting in a decrease of ELISA signal of JM403 of 58 ±  6%. 
These concentrations (1:4 dilution in Fig. 2) were used for all 
further experiments.
The addition of SOD to the HX and XO mixture dose-depend- 
ently prevented loss of the anti-HS signal in ELISA (Fig. 3A). 
Since SOD inactivates 0 2 > the first oxygen radical formed in 
the cascade of reactions, no additional ROS (H20 2 and *OH) will 
be formed. This indicates that ROS are indeed responsible for 
the decrease in HS recognition by mAh JM403. This experi­
ment, however, does not answer the question which of the 
radicals is primarily responsible. Therefore, we also added 
DMTU to HX-XO. Now, 0 2 and H20 2 are still formed, but ’OH 
radicals are scavenged. DMTU also dose-dependently pre­
vented loss of the anti-HS signal in ELISA (Fig. SB). This was 
corroborated by the finding th a t chelation of Fe3 h by DFO (Fig. 
3C), thus anticipating the formation of *OH radicals by the
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F ig , 4. HS exposed to ROS on polyacrylam ide g rad ien t gel. The
following were used as standards: tetrasaccharides (lane 7), hexasac- 
charides (lane 2), and octasaccharides (lane 3). HS was incubated with 
the following components for 2 h a t 37 °C: reaction buffer (lane 4), 
hypoxanthine (lane 5), xanthine oxidase (lane 6), hypoxanthine and 
xanthine oxidase (lane 7), hypoxathine and xanthine oxidase in the 
presence of either dimethylthiourea, 1 mg/ml (lane 8), superoxide dis- 
mutase, 625 units/ml (lane 9), or deferoxamine 12.5 mg/ml (lane 10), 
hypoxanthine and xanthine oxidase in an iron-free buffer (lane 11). The 
gel was stained with Alcian blue and ammoniacal silver.
T a b le  I
Albu?ninuria} serum albumin} clearance of albumin, and selectivity
index at 0 and 4 weeks after ADR injection (36)
Week 0 Week 4 p value
Albuminuria (mg/24 h) 0.4 ± 0.4 371 ± 89 0.0002
Serum albumin (mg/ml) 32.2 ± 1.8 6.9 ± 2.5 0.0002
Clearance of albumin (/xl/min) 0.01 ± 0.01 43 ± 23 0.0002
Selectivity index 0,68 ± 0.32 0,17 ± 0.06 0.0007
Haber-Weiss reaction, also prevented loss of the anti-HS sig­
nal. When HS was exposed to HX and XO in an iron-free buffer, 
the anti-HS signal remained normal as well. These data clearly 
indicate th a t primarily 'OH radicals are involved in HS alter­
ation in vitro.
Since various HS preparations differ in the degree of N - 
and/or O-sulfation and uronate C-5 epimerization, it was still 
uncertain whether GBM HS is also susceptible to ROS. More­
over, it is not known whether ROS can also alter the core 
protein of GBM HSPG. For that reason, ELISA experiments 
were repeated with HSPG isolated from ra t GBM. We used 
anti-HS mAb JM403 to evaluate the effect of ROS on the HS 
polysaccharide side chain and a polyclonal antibody (BL31) 
against the core protein to assess ROS-mediated damage to the 
core protein. Incubation with HX and XO also resulted in a 
decreased JM403 signal on ra t GBM HSPG. This decrease 
could also be prevented dose-dependently by adding SOD, 
DMTU, and DFO to HX-XO (Fig. 3, D-F) and by incubating HX 
and XO in an iron-free buffer. Oxygen radicals had no effect, 
however, on the recognition of the HSPG core protein by BL31 
(Fig. 3, D-F). These data indicate th a t *OIi radicals are respon­
sible for the decrease of anti-HS binding to GBM HSPG.
Theoretically, two different mechanisms might explain this 
finding. First, ’OH radicals alter the biochemical composition of 
HS, thereby changing the epitopes recognized by mAb JM403. 
Second, “OH radicals depolymerize HS chains into oligosaccha­
rides. Therefore, we evaluated the molecular size of native and 
ROS-exposed HS (from bovine kidney) on PAGE. In addition, 
HS was exposed to ROS in the presence of various scavengers. 
On PAGE, native HS forms a band in the top of the gel (Fig. 4,
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lanes 4). After incubation with 1.84 mM HX and 12.6 milli­
units/ml XO, this pattern changes to a smear down to the level 
of the octasaccharides, indicating depolymerization of HS (lane 
7). Adding either DMTU, SOD, or DFO to HX-XO or incubating 
HX-XO in an iron-free buffer prevented the reduction in mo­
lecular mass (lanes 8-11). HX or XO alone had no effect on HS 
(lanes 5  and 6X From this experiment, we conclude that 'OH 
radicals depolymerize HS into oligosaccharides.
In Vivo Experiments—These results (degradation of HS but 
no effect on the core protein of HSPG) resembled our IF finding 
in various human glomerular diseases (13). To investigate an 
possible role of ROS in vivo, we decided to induce a nephrotic 
syndrome into rats by intravenous injection of ADR, since ROS 
have been suggested to play a role in this disease.
Time Response S tu d y —The characteristics of ADR nephrop­
athy are shown in Table I. The injection of 5 mg/kg BW ADR 
induced a heavy albuminuria and a decrease in serum albumin 
levels. The induced proteinuria was selective, since the selec­
tivity index (clearance of IgG/clearance of albumin) was 0.17 ± 
0.06 a t week 4 (vei'sus 0.68 ± 0.32 at week 0 ,p  < 0.001). This 
indicates a preferential urinary loss of albumin, which might 
be due to loss of negative charges (i.e. HS) from the GBM.
We then analyzed the expression of HS(PG) in the GBM after 
ADR injection. The antibodies directed against the HSPG core 
protein, the HS side chain, and the HS stub generated by 
heparitinase stain the GBM in normal rat kidney sections in a 
bright linear pattern as shown in Fig. 5, A~D. In ADR-treated 
rats, we did not observe a change in the staining for the HSPG 
core protein and HS stubs (Fig. 5, E  and H), In contrast to this, 
the GBM staining with anti-HS mAbs JM403 and KJ865 at 
week 4 decreased to 76 and 57%, respectively, of the pretreat­
ment value (both: p  <0.001; Fig. 5, F  and G). This decrease did 
not occur uniformly but locally and segmentally in the glomer­
uli, To analyze a possible relationship between the develop­
ment of albuminuria and HS loss, in a 5-week time study GBM 
HS staining was analyzed with one of the anti-HS mAbs 
(JM403). During the development of the disease we found a 
progressive loss of GBM HS that stabilized from week 4 onward 
(Fig. 6A). Moreover, we found a significant inverse correlation- 
ship between the GBM HS staining and albuminuria (rs — 
—0.80; p  <  O.OOO'l; Fig. 6B). These findings indicate a normal 
expression of the HSPG core protein as well as an unaltered 
degree of glycanation of the core protein, whereas alterations 
occur within the HS polysaccharide side chain during progres­
sion of the ADR nephropathy.
Treatment with R O S Scavengers—To evaluate whether 
these HS changes were mediated by ROS, we treated rats with 
ROS scavengers for 7 days, starting 6 h before the ADR injec­
tion. We investigated the effect of these ROS scavengers on the 
GBM HS staining 4 weeks after ADR injection, since the de­
crease in HS staining was maximal at this time point. The rats 
treated with SOD had the same degree of albuminuria as the 
rats treated with saline (ANOVA for repeated measurements: 
p  = 0,88 versus saline). DMTU, however, ameliorated the ADR- 
induced albuminuria (ANOVA for repeated measurements: p  = 
0.0018 versus saline; Fig, 7A). The GBM staining of HS with 
mAbs JM403 and KJ865 for the scavenger-treated groups are 
shown in Fig. IB. After treatment with DMTU, a significantly 
higher GBM staining for JM403 and KJ865 (Fig. 5, J  and K) 
was found compared with the treatment with saline (Fig. 5, F  
and G). SOD, however, had no effect on the GBM staining with 
these antibodies. The GBM staining for the HSPG core protein 
and HS stubs after heparitinase digestion remained unchanged 
in all groups (see Fig. 5, A, E f and I  versus D , H> and L  
respectively). These data suggest tha t hydroxyl radicals are 
involved in both albuminuria and GBM HS loss.
DISCUSSION
In this study, we have shown that in vitro exposure to ROS 
of both HS and HSPG isolated from ra t GBM results in alter­
ations of HS leading to a decreased recognition by a specific 
anti-HS mAb in ELISA. PAGE revealed that HS was depoly­
merized by ROS. Addition of specific scavengers of hydroxyl 
radicals prevented this depolymerization both in ELISA and in 
PAGE. This indicates that hydroxyl radicals are responsible for 
this effect. Other investigators have also shown that ROS can 
cause depolymerization of glycosaminoglycans (19-23). Most 
studies focused on hyaluronic acid and heparin which are in­
deed depolymerized by ROS (21-23, 42-44), but little is known 
about the susceptibility of HS to ROS.
We observed in ADR nephropathy a progressive albuminuria 
that was accompanied by an increase in selectivity, compatible 
with the loss of negative charges from the GBM. The number of 
HSPG core molecules and HS side chains was unaltered, but 
there was a decrease of the GBM staining by two anti-HS mAbs 
which recognize different domains in the HS side chain. In 
addition, this loss of HS staining correlated with albuminuria. 
Treatment with the hydroxyl radical scavenger DMTU resulted 
in an amelioration of albuminuria and a partial prevention of 
the loss in GBM HS staining. This is in line with our in vitro 
findings that hydroxyl radicals can induce depolymerization of 
HS. On the basis of these results, we postulate that the ensuing 
albuminuria is (at least partly) due to the depolymerization of 
HS, leading to loss of HS from the GBM. In various human and 
experimental proteinuric glomerulopathies, loss of HS staining 
in the GBM has been observed as well (13-15, 45). Moreover, 
the correlation between albuminuria and loss of HS staining is 
not unique for ADR nephropathy, since we found a similar 
correlation in murine lupus nephritis (14), active Heymann 
nephritis (45), and in patients with diabetic nephropathy (15). 
This suggests that, besides other postulated mechanisms (14— 
16), depolymerization of GBM HS by ROS could play a role in 
other glomerulopathies as well. This is substantiated by the 
beneficial effects of ROS scavengers, not only in ADR nephrop­
athy (34, 39) but also in various other experimental models of 
glomerulopathy (46), such as purine aminonucleoside nephro­
sis (26), passive Heymann nephritis, (27) and anti-GBM ne­
phritis (28). Therefore, depolymerization of HS by ROS could be 
a common mechanism responsible for HS loss and proteinuria 
in these diseases.
In contrast to DMTU, SOD had no effect on albuminuria and 
HS staining in our hands. Data on the anti-proteinuric effect of 
SOD in ADR nephropathy in the literature are conflicting. 
Okasora et a l . (47) reported a beneficial effect, whereas Berto- 
latus et al. (34) found no protection, even with SOD conjugated 
to polyethylene glycol, which has been shown to enhance the 
effects of SOD by prolonging its half-life (48, 49). The finding 
that SOD was not effective may be a consequence of the rela­
tively large dimensions of the enzyme which prevent easy pas­
sage across the cell membrane (50).
Apart from degradation of HS, ROS could also exert a direct 
toxic effect on the glomerular epithelial cell resulting, for ex­
ample, in a structurally altered HS. Indeed, an increase in the 
extent of sulfation of HS could be an alternative explanation for 
the decrease in GBM HS staining that we found. Both anti-HS 
mAbs that we used in our study recognize exclusively low- or 
non-sulfated domains in the HS side chain. mAb JM403 is 
directed against a low-sulfated domain of HS containing an 
AT-unsubstituted glucosamine unit (12), whereas mAb KJ865 is 
directed against AT-acetylated domains ofHS (31). Increase of 
HS sulfation greatly diminishes recognition by both mAbs and 
thus might explain loss of GBM staining. HS oversulfation,
Normal ADR ADR-DMTU
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F ig . 5. GBM HSPG staining of normal rats or rats with ADR nephropathy treated either w ith saline or dimethylthiourea. Indirect 
IF on kidney sections of normal rats (A-D), saline-treated ADR rats (E-H), or dimethylthiourea-treated ADR rats (I-L) wi th antibodies directed 
against the following epitopes of HSPG; A>Et and I, HSPG core protein BL31; B, F , and J> anti-HS mAb JM403 in a double staining; C, Gt and 
K , anti-HS mAb KJ865; D, H, and L } heparitinase-created HS-stub (mAb 3G10) (magnification: 150 x).
26740 Hydroxyl Radicals Depolymerize Glomerular H eparan Sulfate
250
§ 200 -
1CO
5  150 -
Vi
100
500
Time (weeks)
250
200 -
150 -
100
B
0 100 200 300 400 500
Albuminuria (mg/24 h)
F ig. 6. A, time course of GBM HS staining in ADR nephropathy. Rats 
received a single intravenous injection of 5 mg/kg ADR at week 0. GEM 
HS staining was evaluated in indirect IF with anti-HS mAb JM403, 
Maximal score is 250 arbitrary units. B„ correlation between albumi­
nuria and GBM HS staining in ADR nephropathy.
however, seems not very likely, since it is difficult to correlate 
this to an increased GBM permeability. This hypothesis is 
contradicted as well by the loss of anionic sites that were found 
in ADR nephropathy (51). Moreover, our ¿71 vitro data convinc­
ingly show the susceptibility of GBM HS to degradation by 
ROS. In a related model, however, puromycin aminonucleoside 
nephrosis, a higher [35S]sulfate incorporation into glomerular 
HS was found (suggesting over sulfation of glomerular HS) (52).
What could be the physiological meaning of HS susceptibility 
to ROS? GBM HS contains large JV-acetylated stretches (rec­
ognized by KJ865), which are very sensitive to ROS (23). This 
could mean that HS functions as an antioxidant in the GBM? 
such that other molecules are protected from degradation by 
ROS. This anti oxidant effect has also been shown for heparin 
and hyaluronic acid (42, 43, 53). One can only speculate on the 
physiological effects of the (by depolymerization) released HS 
oligosaccharides. It is known that HS can function as a anchor­
age molecule for growth factors, such as basic fibroblast growth 
factor (54). After degradation of HS, these growth factors would 
be set free and activate glomerular epithelial and/or mesangial 
cells. Released HS oligosaccharides could also exert a local 
impact on the coagulation, whereas in the GBM loss of HS 
could lead to clogging (55).
Our present study provides evidence that ROS-mediated HS 
depolymerization plays a role in ADR nephropathy and is cor-
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Fig, 7, A, effect of ROS scavengers on ADR-induced albuminuria. 
Rats received a single intravenous injection of 5 mg/kg ADR at week 0 
and were treated with either dimethylthiourea (•), superoxide dis- 
mutase (A), or saline (□) twice daily for 7 days, starting 6 h before ADR 
injection. Note that DMTU significantly reduces albuminuria, pointing 
to a role for hydroxyl radicals. * p = 0.0018 versus saline, ANOVA for 
repeated measurements. B , effect of RCS scavengers on GBM HS stain­
ing in ADR nephropathy. Indirect IF on kidney sections of normal rats 
M  and ADR rats treated with either saline (□), superoxide dismutase 
(■), or dimthylthiourea (H). Indirect IF on kidney sections was per­
formed with. anti-HS mAbs JM403 (left) and KJ865-treated rats (right). 
Maximal score was 250 arbitrary units. * p — 0.03 versus saline-treated 
rats.
related to GBM permeability. Since HS interacts with other 
basement membrane components, such as collagen IV and 
laminin, it is an important factor in the assembly and integrity 
of basement membranes and is consequently a determ inant for 
the charge- as well as for the size-dependent permeability 
(55-57). Since ROS are generated by various mechanisms in 
proteinuric glomerular diseases, it is probable th a t this mech­
anism is operative in different glomerulopathies resulting in an 
increased permeability to macromolecules.
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